Date: 2012-10-24
Type of information: IPO
Company: Nanobiotix (France)
Investors:
Amount: € 20 million
Funding type: IPO
Planned used: These funds are intended to provide the company with additional resources to fund and develop its strategy to become a leading provider of nanomedicine, including to 4 recruit staff to strengthen the workforce of the clinical department, to support the use of subcontractors (ie, contract research organizations conducting certain stages of preclinical and clinical programs and contract manufacturing organizations for batch production preclinical NBTXR3) and the implementation of clinical trials directly by the company including the completion of the pilot study course on soft tissue sarcoma and the launch of a second indication of the cancer of the head and neck. A phase trial is currently ongoing and results of this trial should be available by the end of the year (See http://biopharmanalyses.fr/clinical-trails/?pageid=210)
Others: Nanobiotix, a French company that develops pioneering Nanomedicine NanoXray for the local treatment of cancer, has announced its successful IPO for the admission of its shares on the regulated market of NYSE Euronext Paris, compartment C. After full exercise of the extension option and the over-allotment option, the total gross proceeds of the capital increase amounted to € 14.17 million. This price represents a market capitalization of € 64 million.
Therapeutic area: Cancer - Oncology
